Plain-English translation of NCT05603104 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether people with schizophrenia, major depression, or bipolar depression should move to stronger, third-line treatments earlier—like for schizophrenia or esketamine for depression—when their first medication doesn't work. Right now, doctors typically try a second-line medication first before moving to these more intensive options. The study wants to know if skipping ahead to the stronger medication sooner helps people feel better faster.
Many people with these conditions don't respond well to their first prescribed medication, and doctors aren't sure when to switch to more powerful treatments. This research aims to find out whether using this medication earlier could help people recover faster and avoid months or years of trying ineffective treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either continue with a standard second-line medication or switch to a more intensive third-line treatment. If you have schizophrenia, you may be switched to ; if you have depression, you may receive a new antidepressant plus esketamine nasal spray or infusions twice weekly. You'll visit the study clinic regularly so doctors can monitor how well the treatment is working and watch for any side effects. The study involves rating your symptoms over time to compare how the two treatment approaches work.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Israel